Mode
Text Size
Log in / Sign up
Phase 3 N=87 Treatment

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

PTSD

Enrolled (actual)
87
Serious AEs
1.2%
Results posted
Nov 2024
Primary outcome: Primary: Change From Baseline to Visit 16 in PCL-5 Total Score — -14.92 score on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Midomafetamine HCl (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Resilient Pharmaceuticals
Primary completion
Nov 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline to Visit 16 in PCL-5 Total Score
-14.92
SECONDARY
Change From Baseline to Visit 16 in Sheehan Disability Scale (SDS) Total Score
-4.10

Summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with PTSD who received placebo in a prior MDMA-assisted therapy study. The main question it aims to answer is: Do PTSD symptoms decrease in people who receive a flexible dose of MDMA (120 or 180 mg MDMA HCl) with therapy in three sessions? Participants will undergo three preparatory therapy sessions without any study drug, then three MDMA-assisted therapy sessions with a flexible dose of 80 or 120 mg, followed by three integrative therapy sessions without study drug after each MDMA-assisted therapy session.

Eligibility Criteria

Inclusion Criteria

  • Were previously enrolled in a parent study and (meet one of the following):
  • At time of unblinding, their treatment assignment was to the placebo arm; or,
  • Did not begin Experimental Sessions due to the COVID-19 global pandemic or other unforeseen circumstances;
  • Completed fewer than three Experimental Sessions prior to Study Termination due to the COVID-19 global pandemic or other unforeseen circumstances.
  • Are considered in good standing with the study site at which they enrolled in a parent study; if, in the opinion of the investigator, therapy team, and Medical Monitor, the participant was compliant with protocol requirements, even if they were unable to complete all study visits.
  • Are at least 18 years old
  • Are fluent in speaking and reading the predominantly used or recognized language of the study site
  • Are able to swallow pills
  • Agree to have study visits recorded, including Experimental Sessions, Independent Rater assessments, and non-drug psychotherapy sessions
  • Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.
  • Must agree to inform the investigators within 48 hours of any medical conditions and procedures
  • If of childbearing potential, must have a negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate birth control through 10 days after the last Experimental Session.
  • Must not participate in any other interventional clinical trials during the duration of the study
  • Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to Experimental Sessions.
  • Must be willing to remain overnight at the study site after each Experimental Session and be driven home after, and commit to medication dosing, therapy, and study procedures.

Exclusion Criteria

  • Are not able to give adequate informed consent Have uncontrolled hypertension
  • Have a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds [ms] in males and >460 ms in females corrected by Fridericia formula)
  • Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Have evidence or history of significant medical disorders, such as myocardial infarction, cerebrovascular accident, or aneurysm
  • Have symptomatic liver disease
  • Have recent history of hyponatremia or hyperthermia
  • Weigh less than 48 kilograms (kg)
  • Are pregnant or nursing, or are of childbearing potential and are not practicing an effective means of birth control
  • Have an active illicit or prescription drug substance use disorder within 12 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04714359). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search